Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 67

6 October 2019 Tablets & Capsules correction In Robert Sedlock 's September article "Advantages of using an instru- mented R&D tablet press," we mis- identified several of the units of mea- sure in Figure 1 on page 23. The units were listed as millipascals for tensile strength in Figure 1a and 1c and for compaction pressure in Figure 1a and 1b. The units should have been mega- pascals. We apologize for the error. research AI produces potential fibrosis treatment in 3 weeks HONG KONG — Scientists at Insilico Medicine have developed an artificial intelligence (AI) drug discovery system that was able to produce a potential fibrosis treat- ment in 21 d ays, according to a study published in the September issue of Nature Biotech nology. T he system used a creative AI algorithm that optimizes synthetic feasibility, novelty, and biological activity to discover potent inhibitors of dis- coidin domain receptor 1, a kinase target associated with fibrosis and other diseases. One lead candidate was tested in mice and demon- strated favorable pharmacokinetics. T he AI system has the potential to optimize drug development and could result in huge cost savings for pharmaceutical companies. markets Pharmaceutical industry to spur European desiccant market growth DUBLIN, Ireland— Continued pharmaceutical industry expansion is expected to cause the European pharmaceutical desiccant market to grow at a compound annual rate of 4.59 percent per year through 2027, according to a report by Research and Markets. Increases in income levels and government healthcare initiatives are expected to increase the availability and affordability of medicines, which will fuel pharma- ceutical industry growth and lead to an increased use of pharmaceuti- cal desiccants. The report identifies Oker-Chemie, Rotor Source, W. R. Grace, Munters, Sanner, and Pro- Flute as major players in the Euro- pean desiccant market. 3D-printed drug market to reach $437 million LON DON, UK—T he global 3D-printed drugs market is expected to reach $437.04 million by 2025, growing at a compound annual rate of 7 percent, according to a report by Industry Stats Report. A key fac- tor driving the market growth is increasing demand for quickly solu- ble drugs that disperse easily in the patient's mouth. Key market players include 3D Printer Drug Machine, Aprecia Pharmaceuticals, Hewlett Packard Caribe, GlaxoSmithKline, FabRx, and Cycle Pharmaceuticals.

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC1019